CN1686294A - Medicinal composition for treating coronary heart disease stenocardia - Google Patents
Medicinal composition for treating coronary heart disease stenocardia Download PDFInfo
- Publication number
- CN1686294A CN1686294A CN 200510041884 CN200510041884A CN1686294A CN 1686294 A CN1686294 A CN 1686294A CN 200510041884 CN200510041884 CN 200510041884 CN 200510041884 A CN200510041884 A CN 200510041884A CN 1686294 A CN1686294 A CN 1686294A
- Authority
- CN
- China
- Prior art keywords
- parts
- fine powder
- heart disease
- coronary heart
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A Chinese medicine in the form of particle, tablet, capsule, softcapsule, etc for treating coronary heart disease and angina pectoris is prepared from 5 Chinese-medicinal materials including red sage root, cloves, borneol, etc through conventional process.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly a kind for the treatment of coronary heart disease and angina pectoris compositions that is used for the treatment of.
Background technology
Angina pectoris is a kind of commonly encountered diseases and frequently-occurring disease, has seriously endangered the human particularly health and the life of mid-aged population.Chinese patent gazette disclosed the name of being declared by the applicant to be called " a kind of Chinese patent medicine that is used for the treatment of angina pectoris ", publication number was 1452998 patent application on November 5th, 2003, the weight proportion of forming each herbal medicine raw material of the described Chinese patent medicine of invention is: 10～300 unit of weights of Fructus Choerospondiatis, 20～200 unit of weights of Radix Salviae Miltiorrhizae, 20～200 unit of weights of Flos Caryophylli, 2～40 unit of weights of Borneolum Syntheticum, 2～60 unit of weights of Concretio Silicea Bambusae, but we find that the effect of this Chinese patent medicine is desirable not enough in actual application.In nearly 2 years time, we are on original basis, grope by a large amount of experiments, found best set of dispense ratio, clinical pharmacodynamic experiment effect is more remarkable, we routinely technology made dosage forms such as granule, tablet, hard capsule, soft capsule, drop pill, oral liquid.
Summary of the invention
The objective of the invention is to: provide a kind of curative effect to treat the treating coronary heart disease and angina pectoris compositions more significantly.
The present invention is achieved in that according to components by weight percent and calculates, pharmaceutical composition of the present invention be by following materials of weight proportions routinely prepared form: 480 parts of Fructus Choerospondiatis, 240 parts of Radix Salviae Miltiorrhizaes, 60 parts of Flos Caryophyllis, 30 parts of Borneolum Syntheticums, 30 parts of Concretio Silicea Bambusaes.Described pharmaceutical composition can be an acceptable forms on the pharmaceutics, for example dosage forms such as granule, tablet, hard capsule, soft capsule, drop pill, oral liquid and injection.
With the capsule is example, Pharmacodynamic test of active extract proves: 30 parts of 480 parts of raw material weight proportioning Fructus Choerospondiatis, 240 parts of Radix Salviae Miltiorrhizaes, 60 parts of Flos Caryophyllis, 30 parts of Borneolum Syntheticums, Concretio Silicea Bambusae are with former invention weight proportion 1: 10 parts of Fructus Choerospondiatis, 20 parts of Radix Salviae Miltiorrhizaes, 20 parts of Flos Caryophyllis, 2 parts of Borneolum Syntheticums, 2 parts of Concretio Silicea Bambusaes and former invention weight proportion 2: 300 parts of Fructus Choerospondiatis, 200 parts of Radix Salviae Miltiorrhizaes, 200 parts of Flos Caryophyllis, 40 parts of Borneolum Syntheticums, Concretio Silicea Bambusae are compared for 60 parts, and results of pharmacodynamic test is significantly increased.
Pharmacodynamic test of active extract
One, purpose: contrast former invention pharmaceutical composition, observe the present invention to laboratory animal myocardial ischemia, anoxia enduring and hemorheological influence.
Two, method: utilize pituitrin to bring out the rat heart muscle ischemia, and duplicate rat acute " blood stasis " model of a syndrome and use normal pressure anoxia enduring experimental technique with epinephrine, observe former invention pharmaceutical composition and oral administration of the present invention to the rat model preventive and therapeutic effect.The result: both all can resist pituitrin and cause Acute Myocardial Ischemia in Rats and sexually revised tangible preventive effect, improve the mice hypoxia-bearing capability, have preventive and therapeutic effect, the present invention obviously to be better than former invention pharmaceutical composition to rat " blood stasis " card.Illustrate that the present invention can obviously improve expeirmental myocardial ischemia, reduce myocardial oxygen consumption and improve hemorheological property.
1 material and method
1.1 animal Wstar rat, low-priced male dual-purpose, body weight 200 ± 30g; Kunming mouse. body weight 20 ± 2g.
1.2 medicine
A, raw material:
A, of the present invention group: by Fructus Choerospondiatis 480g, Radix Salviae Miltiorrhizae 240g, Flos Caryophylli 60g, Borneolum Syntheticum 30g, Concretio Silicea Bambusae 30g preparation.(by 480 parts of Fructus Choerospondiatis of the present invention, 240 parts of Radix Salviae Miltiorrhizaes, 60 parts of Flos Caryophyllis, 30 parts of Borneolum Syntheticums, 30 parts of proportionings of Concretio Silicea Bambusae)
1 group of b, former invention: by Fructus Choerospondiatis 156g, Radix Salviae Miltiorrhizae 311g, Flos Caryophylli 311g, Borneolum Syntheticum 31g, Concretio Silicea Bambusae 31g preparation.(by former invention weight proportion 1: 10 parts of Fructus Choerospondiatis, 20 parts of Radix Salviae Miltiorrhizaes, 20 parts of Flos Caryophyllis, 2 parts of Borneolum Syntheticums, 2 parts of proportionings of Concretio Silicea Bambusae)
2 groups of c, former inventions: by Fructus Choerospondiatis 315g, Radix Salviae Miltiorrhizae 210g, Flos Caryophylli 210g, Borneolum Syntheticum 42g, Concretio Silicea Bambusae 63g preparation.(by former invention weight proportion 2: 300 parts of Fructus Choerospondiatis, 200 parts of Radix Salviae Miltiorrhizaes, 200 parts of Flos Caryophyllis, 40 parts of Borneolum Syntheticums, 60 parts of proportionings of Concretio Silicea Bambusae)
B, method for making:
Get Fructus Choerospondiatis 1/4 amount, be ground into fine powder, be divided into two parts, standby; The residue Fructus Choerospondiatis is ground into coarse powder, use 70% ethanol percolation, collects percolate, and recovery ethanol is concentrated into the relative density 1.30～1.35 of 50 ℃ of surveys, adds a Fructus Choerospondiatis fine powder, mixes thoroughly, and 60 ℃ of vacuum dryings are ground into fine powder.Radix Salviae Miltiorrhizae extracts 3 times, adds 95% alcohol reflux 1.5 hours for the first time, filter, and filtrate recycling ethanol, the relative density that is concentrated into 55～60 ℃ of surveys is 1.30; Add for the second time 50% alcohol reflux 1.5 hours, filter; Decoct with water 2 hours for the third time, filter, merge second and third time filtrate, reclaim ethanol, the relative density that is concentrated into 55～60 ℃ of surveys is 1.40, merge with primary concentrated solution, mixing, the relative density that is concentrated into 55～60 ℃ of surveys is 1.20～1.30, add another part Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Concretio Silicea Bambusae is ground into fine powder, is divided into two parts, and standby: Flos Caryophylli is used vapor distillation, extracts volatile oil, evenly spray in a Concretio Silicea Bambusae fine powder, and mixing, airtight; Borneolum Syntheticum mixes with another part Concretio Silicea Bambusae fine powder, is ground into fine powder, with above-mentioned medicated powder mixing, promptly.
More than standby with the normal saline wiring solution-formings before the experiment of three groups of medicines.
1.3 the automatic electrocardiograph of instrument ECG6551 single track; WDY-D voltage stabilization and current stabilization erythrocyte electrophoresis instrument, the SA-C type is adjustable constant pressure automatic drain capillary viscosimeter.
1.4.1 influence to rat heart muscle ischemia due to the pituitrin
Get rat, pentobarbital sodium 30mg/kg contrasts intraperitoneal anesthesia, traces limbs II and leads ECG (1mm:0.1mv, chart speed 2.5mm/s), by tail vein injection pituitrin 1U/kg, in 10s, inject and finish, trace 15s, 30s then immediately, 1,3,5.10,15 and the ECG of 2min.The rat rejecting that ischemic change ECG ST section do not occurred need not.After 1 week, get 40 of garbled rats, be divided into 4 groups at random: normal saline group, of the present invention group, 1 group of former invention, 2 groups of former inventions.Successive administration (every kg body weight crude drug amount 3g) 7 days, last administration 1h, by most intravenous injection pituitrin, method is the same after the intraperitoneal anesthesia.Trace electrocardiogram immediately, observe the ST section and change.See Table 1
Table 1 the present invention causes the antagonism of acute myocardial ischemia to pituitrin
| Group | ?n | Before the medicine | (min) ECG ST section (mv) behind the ischemia | |||||||
| ????0.25 | ????0.5 | ????1 | ???3 | ???5 | ????10 | ???15 | ???20 | |||
| Normal saline | ?10 | ??0.03± ????0.06 | ????0.14± ????????0.04 | ????0.15± ????????0.04 | ????0.17± ????????0.06 | ???0.17± ??????0.06 | ???0.19± ??????0.05 | ????0.21± ????????0.06 | ???0.18± ??????0.04 | ???0.18± ??????0.16 |
| Of the present invention group | ?10 | ??0.04± ????0.02 | ????0.05± ?????????0.05 ② | ????0.06± ????????0.05 ② | ????0.06± ????????0.05 ② | ???0.07± ??????0.05 ② | ???0.08± ??????0.05 ② | ????0.11± ????????0.02 ② | ???0.10± ??????0.03 ② | ???0.11± ??????0.05 ② |
| 1 group of former invention | ?10 | ??0.02± ????0.02 | ????0.11± ????????0.06 ③ | ????0.11± ????????0.04 ②③ | ????0.12± ????????0.03 ②④ | ???0.13±??? ??????0.06 ②③ | ???0.13±??? ??????0.04 ②③ | ????0.12± ????????0.05 ② | ???0.11± ??????0.06 ② | ???0.11± ??????0.05 ② |
| 2 groups of former inventions | ?10 | ??0.06± ????0.03 | ????0.09± ?????????0.06 ① | ????0.10±?? ????????0.04 ① | ????0.10± ????????0.03 ② | ???0.10± ??????0.03 ② | ???0.12± ??????0.03 ② | ????0.11± ????????0.03 ② | ???0.09± ??????0.03 ② | ???0.08± ??????0.03 ② |
Annotate: with the normal saline group relatively. 1. p＜0.05; 2. p＜0.01.With of the present invention group of comparison, 3. p＜0.05; 4. p＜0.01.
Show by this experiment, with the normal saline group relatively, three groups of medicines all can significantly resist the variation of the ECG ST section that pituitrin causes.And with of the present invention group relatively, the variation of the ECG ST section that the antagonism pituitrin that former invention is 1 group causes is 0.25,0.5,1,3,5 period all obviously is weaker than of the present invention group far away, and the variation of the ECG ST section that the antagonism pituitrin of 2 groups of former inventions causes also slightly is weaker than of the present invention group, but no difference of science of statistics.
1.4.2 influence to mice normal pressure anoxia enduring
Get 40 of mices, grouping is the same, and each group is put into the 250ml wide mouthed bottle that fills sodica calx 10g with mice behind gastric infusion (the every kg body weight crude drug amount 6g) 1h respectively, and the sealing bottleneck is observed each Mus death time (is index with the respiratory arrest), calculates the time-to-live.
Table 2 the present invention is to the influence of mice normal pressure anoxia enduring
| Group | ???n | Time-to-live |
| Normal saline | ???10 | ?????37.6±8.7 |
| Of the present invention group | ???10 | ?????48.3±3.9 ② |
| 1 group of former invention | ???10 | ?????42.4±4.7 ①④ |
| 2 groups of former inventions | ???10 | ?????44.5±5.7 ①③ |
Annotate: with the normal saline group relatively. 1. p＜0.05; 2. p＜0.01.With of the present invention group of comparison, 3. p＜0.05; 4. p＜0.01.
Show that by this experiment three groups of medicines mice normal pressure hypoxia-bearing capability that all is significantly improved reduces the effect of myocardial oxygen consumption.And with of the present invention group relatively, the raising to mice normal pressure hypoxia-bearing capability that former invention is 1 group is weaker than of the present invention group far away, and the raising to mice normal pressure hypoxia-bearing capability of 2 groups of former inventions also is weaker than of the present invention group.
1.4.3 rat " blood stasis " is demonstrate,proved hemorheological influence
Get 50 of rats, be divided into 5 groups at random: normal saline group, " blood stasis " model group, of the present invention group, 1 group of former invention, 2 groups of former inventions.Normal saline group and model group are irritated stomach NS10mg/kg, continuous 7 days every day.The 7th day subcutaneous injection 0.1% epinephrine 0.08mg/kg of model group immerses frozen water 5min with rat behind the 2h, stops eating after injecting epinephrine 1 time behind the 2h again, and Yu Cichen gets anticoagulation and surveys hemorheology index.All the other organized separately successive administration (every kg body weight crude drug amount 3g) 7 days, surveyed hemorheology index as stated above in the 7th day
Table 3 the present invention is to the hemorheology influence of syndrome of blood stasis rat
| Group | Whole blood reduced viscosity (ratio) | Whole blood viscosity (ratio) | Plasma viscosity (ratio) | Fibrinogen (mg/dl) | Packed cell volume (%) | Erythrocyte electrophoretic time |
| Normal saline | ??12.0±1.9 | ???7.1±1.2 | ???1.7±0.1 | ??307.8±23.3 | ??51.7±3.0 | ??20.6±2.8 |
| Model | ??15.8±4.4 ① | ???9.1±2.8 ① | ???2.1±0.2 ② | ??393.8±20.3 ?? ① | ??59.3±5.9 ?? ① | ??24.2±3.0 ① |
| The present invention | ??11.2±3.0 | ???6.8±1.7 ③ | ???1.6±0.2 ④ | ??335.4±38.4 ?? ④ | ??50.3±6.8 ?? ③ | ??21.5±2.6 ③ |
| Former invention 1 | ??13.6±4.4 | ???8.4±1.8 | ???2.3±0.3 | ??368.7±22.6 ?? ③⑤ | ??59.1±6.8 ?? ③⑤ | ??22.9±2.3 |
| Former invention 2 | ??12.0±3.2 ③ | ???7.1±1.7 | ???1.8±0.2 ④ | ??353.8±20.5 ?? ③ | ??50.4±9.2 | ??22.0±1.8 |
Annotate: model group and normal saline group ratio, 1. p＜0.05; 2. p＜0.01.Of the present invention group with model group ratio, 3. p＜0.05; 4. p＜0.01.With of the present invention group of comparison, 5. p＜0.05; 6. p＜0.01.
Three groups of medicines can obviously improve the part index number in the hemorheology, wherein obvious with of the present invention group of improvement, every hemorheology index in of the present invention group all improves significantly than other two groups of medicines, wherein all more former invention of Fibrinogen, packed cell volume has significant difference for 1 group, with 2 groups of former inventions there was no significant difference then, 1,2 groups of there was no significant differences of other indexs and former invention.
The present invention is prepared into dosage forms such as comprising granule, tablet, hard capsule, soft capsule, drop pill and oral liquid with common process.
The specific embodiment
1, process for producing granula: get Fructus Choerospondiatis 360g, be ground into fine powder, be divided into two parts, standby; Get the 1080g Fructus Choerospondiatis again and be ground into coarse powder, use 70% ethanol percolation, collect percolate, reclaim ethanol, be concentrated into relative density 1.30～1.35 (50 ℃), add a Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Radix Salviae Miltiorrhizae extracts 3 times, adds alcohol reflux 1.5 hours for the first time, filter, and filtrate recycling ethanol, being concentrated into relative density is 1.30 (55～60 ℃); Add for the second time 50% alcohol reflux 1.5 hours, filter; Decoct with water 2 hours for the third time, filter, merge second and third time filtrate, reclaim ethanol, being concentrated into relative density is 1.40 (55～60 ℃), merge with primary concentrated solution, mixing, being concentrated into relative density is 1.20～1.30 (55～60 ℃), add another part Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Concretio Silicea Bambusae 90g is ground into fine powder, is divided into two parts, and is standby.Flos Caryophylli 180g vapor distillation extracts volatile oil, evenly sprays in a Concretio Silicea Bambusae fine powder, and mixing, airtight; Borneolum Syntheticum 90g mixes with another part Concretio Silicea Bambusae fine powder, is ground into fine powder, adds dextrin 1100g, steviosin 1g, and with above-mentioned medicated powder mixing, pack is made 1000 bags, every bag of 2g.Oral, one time 1 bag, 3 times on the one, warm water delivery service.
2, method for preparing tablet thereof: get Fructus Choerospondiatis 120g, be ground into fine powder, be divided into two parts, standby; Get the 360g Fructus Choerospondiatis again and be ground into coarse powder, use 70% ethanol percolation, collect percolate, reclaim ethanol, be concentrated into relative density 1.30～1.35 (50 ℃), add a Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Radix Salviae Miltiorrhizae 240g extracts 3 times, adds alcohol reflux 1.5 hours for the first time, filter, and filtrate recycling ethanol, being concentrated into relative density is 1.30 (55～60 ℃); Add for the second time 50% alcohol reflux 1.5 hours, filter; Decoct with water 2 hours for the third time, filter, merge second and third time filtrate, reclaim ethanol, being concentrated into relative density is 1.40 (55～60 ℃), merge with primary concentrated solution, mixing, being concentrated into relative density is 1.20～1.30 (55～60 ℃), add another part Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Concretio Silicea Bambusae 30g is ground into fine powder, is divided into two parts, and is standby.Flos Caryophylli 60g vapor distillation extracts volatile oil, evenly sprays in a Concretio Silicea Bambusae fine powder, and mixing, airtight; Borneolum Syntheticum 30g mixes with another part Concretio Silicea Bambusae fine powder, is ground into fine powder, adds starch 100g, with above-mentioned medicated powder mixing, tabletting, makes 1000, every 0.4g.Oral, one time 3,3 times on the one, warm water delivery service.
3, hard capsule preparation method: get 120 parts of Fructus Choerospondiatis, be ground into fine powder, be divided into two parts, standby; Remain 360 portions of Fructus Choerospondiatis and be ground into coarse powder, use 70% ethanol percolation, collect percolate, reclaim ethanol, be concentrated into relative density 1.30～1.35 (50 ℃), add a Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Radix Salviae Miltiorrhizae extracts 3 times, adds alcohol reflux 1.5 hours for the first time, filter, and filtrate recycling ethanol, being concentrated into relative density is 1.30 (55～60 ℃); Add for the second time 50% alcohol reflux 1.5 hours, filter; Decoct with water 2 hours for the third time, filter, merge second and third time filtrate, reclaim ethanol, being concentrated into relative density is 1.40 (55～60 ℃), merge with primary concentrated solution, mixing, being concentrated into relative density is 1.20～1.30 (55～60 ℃), add another part Fructus Choerospondiatis fine powder, mix thoroughly, 60 ℃ of vacuum dryings are ground into fine powder.Concretio Silicea Bambusae is ground into fine powder, is divided into two parts, and is standby.Flos Caryophylli is used vapor distillation, extracts volatile oil, evenly spray in a Concretio Silicea Bambusae fine powder, and mixing, airtight; Borneolum Syntheticum mixes with another part Concretio Silicea Bambusae fine powder, is ground into fine powder, with above-mentioned medicated powder mixing, incapsulates, and makes 1000, every 0.3g.Oral, one time 3,3 times on the one, warm water delivery service.
4, soft capsule preparation method: Fructus Choerospondiatis 80g carries out percolation with 70% ethanol of 10 times of amounts, collects percolate, is evaporated to thick paste; Radix Salviae Miltiorrhizae 40g earlier carries out percolation with the sour water (0.01mol/L HCl) of 12 times of amounts, the collection percolate, and after filtrate was adsorbed with the AB-8 resin, sour water was washed behind 4 column volumes with 3 column volumes of 95% ethanol elution, collects pure washing liquid.95% ethanol percolation of the 14 times of amounts of Radix Salviae Miltiorrhizae residue reuse behind the water percolation is collected percolate, merges with above-mentioned eluent, is evaporated to thick paste; Concretio Silicea Bambusae 5g water extraction 2 times, each amount of water is 10 times of medical material amount, and be 2 hours heat time heating time, filters, and merging filtrate is evaporated to thick paste; Merge above medicinal liquid, concentrate, behind 60 ℃ of vacuum dryings, be ground into fine powder, standby.Flos Caryophylli 10g extracts volatile oil with vapor distillation, and is standby.It is an amount of to get the adjuvant soybean oil, adds 5% Cera Flava, after heating makes dissolving, adds the mixed extract of Fructus Choerospondiatis, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae, stirs evenly the back and adds Flos Caryophylli volatile oil and Borneolum Syntheticum fine powder 5g, and colloid mill grinds well, and is pressed into 1000 of soft capsules, every 0.3g.Oral, one time 3,3 times on the one, warm water delivery service.
5, drop pill preparation method: Fructus Choerospondiatis 80g carries out percolation with 70% ethanol of 10 times of amounts, collects percolate, is evaporated to thick paste; Radix Salviae Miltiorrhizae 40g earlier carries out percolation with the sour water (0.01mol/L HCl) of 12 times of amounts, the collection percolate, and after filtrate was adsorbed with the AB-8 resin, sour water was washed behind 4 column volumes with 3 column volumes of 95% ethanol elution, collects pure washing liquid.95% ethanol percolation of the 14 times of amounts of Radix Salviae Miltiorrhizae residue reuse behind the water percolation is collected percolate, merges with above-mentioned eluent, is evaporated to thick paste; Concretio Silicea Bambusae 5g water extraction 2 times, each amount of water is 10 times of medical material amount, and be 2 hours heat time heating time, filters, and merging filtrate is evaporated to thick paste; Merge above medicinal liquid, concentrate, behind 60 ℃ of vacuum dryings, be ground into fine powder, standby.Flos Caryophylli 10g extracts volatile oil with vapor distillation, and is standby.With Macrogol 4000, put the mixed extract that adds Fructus Choerospondiatis, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae in the water-bath behind the heating and melting, stir evenly the back and add Flos Caryophylli volatile oil and Borneolum Syntheticum fine powder 5g, stir and be transferred to reservoir, airtight and in 70 ℃ of insulations, with the methyl-silicone oil is coolant, makes 1000 of drop pill, every 50mg.Oral, one time 18,3 times on the one, warm water delivery service.
6, oral liquid preparation method: Borneolum Syntheticum 30g adds Tween 80 30ml, stirs evenly, and adds ethanol 80ml stirring and dissolving again, gets Borneolum Syntheticum solution, and is standby; Fructus Choerospondiatis 480g, Radix Salviae Miltiorrhizae 240g, Flos Caryophylli 60g, Concretio Silicea Bambusae 30g decoct with water 3 times, add 10 times of amounts of water at every turn, decoct 1 hour, collecting decoction, filtration, filtrate decompression are concentrated into relative density 1.18 (60 ℃), add ethanol and make and contain alcohol amount and reach 60%, stir evenly, left standstill 24 hours, filter, decompression filtrate recycling ethanol adds Borneolum Syntheticum solution and stirs evenly, and adds water to 1000ml, filter, fill, sterilization, promptly.Every 10ml, oral, one time 1,3 times on the one.
Claims (3)
1, a kind for the treatment of coronary heart disease and angina pectoris compositions that is used for the treatment of, it is characterized in that it be by following materials of weight proportions routinely prepared form:
480 parts of Fructus Choerospondiatis, 240 parts of Radix Salviae Miltiorrhizaes, 60 parts of Flos Caryophyllis, 30 parts of Borneolum Syntheticums, 30 parts of Concretio Silicea Bambusaes.
2, the treating coronary heart disease and angina pectoris compositions that is used for the treatment of according to claim 1, it is characterized in that: described pharmaceutical composition is an acceptable forms on the pharmaceutics.
3, the treating coronary heart disease and angina pectoris compositions that is used for the treatment of according to claim 2, it is characterized in that: described pharmaceutical composition is granule, tablet, hard capsule, soft capsule, drop pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100418846A CN1332700C (en) | 2005-04-01 | 2005-04-01 | Medicinal composition for treating coronary heart disease stenocardia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100418846A CN1332700C (en) | 2005-04-01 | 2005-04-01 | Medicinal composition for treating coronary heart disease stenocardia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686294A true CN1686294A (en) | 2005-10-26 |
| CN1332700C CN1332700C (en) | 2007-08-22 |
Family
ID=35304336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100418846A Active CN1332700C (en) | 2005-04-01 | 2005-04-01 | Medicinal composition for treating coronary heart disease stenocardia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1332700C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100390540C (en) * | 2005-12-08 | 2008-05-28 | 咸阳步长医药科技发展有限公司 | Chinese medicine capsule for treating coronary heart clisease and angina pectoris, and quality control method |
| CN102441118A (en) * | 2010-10-09 | 2012-05-09 | 陕西步长制药有限公司 | Application of medicinal composition in preparing medicaments for treating diabetes mellitus and impaired glucose tolerance |
| CN102614409A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614411A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614410A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614408A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1239194C (en) * | 2002-04-28 | 2006-02-01 | 咸阳步长医药科技发展有限公司 | Chinese patent medicine for treating coronary heart disease and angina pectoris |
-
2005
- 2005-04-01 CN CNB2005100418846A patent/CN1332700C/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100390540C (en) * | 2005-12-08 | 2008-05-28 | 咸阳步长医药科技发展有限公司 | Chinese medicine capsule for treating coronary heart clisease and angina pectoris, and quality control method |
| CN102441118A (en) * | 2010-10-09 | 2012-05-09 | 陕西步长制药有限公司 | Application of medicinal composition in preparing medicaments for treating diabetes mellitus and impaired glucose tolerance |
| CN102441118B (en) * | 2010-10-09 | 2013-07-17 | 陕西步长制药有限公司 | Application of medicinal composition in preparing medicaments for treating diabetes mellitus and impaired glucose tolerance |
| CN102614409A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614411A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614410A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614408A (en) * | 2012-04-25 | 2012-08-01 | 陕西步长制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
| CN102614408B (en) * | 2012-04-25 | 2013-11-20 | 陕西步长高新制药有限公司 | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1332700C (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1332700C (en) | Medicinal composition for treating coronary heart disease stenocardia | |
| CN102579554B (en) | Peanut stem and leaf extract and preparation method as well as application thereof | |
| CN105434583A (en) | Semi-bionic preparation method for Xinkeshu preparations | |
| CN1323712C (en) | Medicine composition for treating cholelithiasis | |
| CN111569011A (en) | New application of traditional Chinese medicine composition and preparation method thereof | |
| CN1686465A (en) | Preparation method of heart boosting pulse restoring Chinese medicinal preparation | |
| CN1939406A (en) | Danshen root drop pills for treating coronary heart disease and preparation thereof | |
| CN113058013A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1178890C (en) | Method for extracting hypericin from Hypericum perforatum and medicine made up using hypericin as main composition | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1316959C (en) | Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method | |
| CN1857492A (en) | Qingxie preparation and its preparing process | |
| CN1931286A (en) | Chinese medicine composition for treating lung cancer caused pain | |
| CN1246020C (en) | Composition for alcohol type fatty liver | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process | |
| CN100358496C (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN1742838A (en) | Xishengteng external-use medicine | |
| CN1742821A (en) | Blood-activating preparation and preparing method | |
| CN101028319A (en) | Chinese-medicine compound preparation against coronary heart disease and its production | |
| CN107693618B (en) | Pharmaceutical composition for treating kidney deficiency and preparation method and application thereof | |
| CN1118278C (en) | Application of ursolic acid in medicine for treating viral hepatitis | |
| CN1292738C (en) | Ginseng-pilose antler dripping pill for tonifying heart and kidney and its preparing method | |
| CN1795923A (en) | Medication composition for treating chronic ulcerative colitis, and preparation method | |
| CN105663529A (en) | Traditional Chinese medicinal composition for treating depression and preparation method of traditional Chinese medicinal composition | |
| CN1490014A (en) | Mangiferin preparation and production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANXI BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BUCHANG MEDICAL SCIENCE + TECHNOLOGY DEVELOPING CO., LTD., XIANYANG CITY Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: Box section 123 West Weiyang road in Xianyang City Patentee after: Shaanxi Buchang Pharmaceutical Co.,Ltd. Address before: Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Patentee before: Buchang Medical & Drug Science & Tech. Development Co., Ltd., Xianyang |